Table 4.

Percentage changes of bone mineral density over followup period by menstrual status, disease flare, new organ damage, use of glucocorticoids, hydroxychloroquine, immunosuppressants, and antiosteoporosis therapies.

Variables	Femoral Neck	Total Hip	Lumbar Spine
Menstrual status at baseline
Postmenopausal, n = 79	−2.31 ± 5.10	−1.40 ± 4.58	−0.55 ± 6.84
Premenopausal, n = 46	−2.57 ± 6.38	−2.00 ± 5.91	−0.74 ± 8.15
p	0.801	0.553	0.893
Transitional menstrual status during followup
Yes, n = 16	−5.80 ± 6.13	−5.26 ± 5.23	−5.38 ± 6.06
No, n = 109	−1.89 ± 5.36	−1.08 ± 4.88	0.08 ± 7.24
p	0.009^*	0.002^*	0.005^*
Flare during followup
Yes, n = 44	−3.48 ± 5.47	−3.44 ± 4.75	−3.10 ± 6.35
No, n = 81	−1.80 ± 5.61	−0.60 ± 5.04	0.72 ± 7.49
p	0.112	0.003^*	0.005^*
New organ damage
Yes, n = 41	−4.22 ± 5.35	−3.30 ± 4.83	−1.84 ± 7.09
No, n = 84	−1.55 ± 5.53	−0.84 ± 5.06	−0.03 ± 7.39
p	0.013^*	0.012^*	0.194
New renal damage
New renal damage, n = 10	−8.03 ± 4.02	−6.10 ± 3.90	−5.16 ± 5.00
New other damage, n = 31	−2.91 ± 5.17	−2.34 ± 4.80	−0.77 ± 7.39
p ^**	0.031^*	0.118	0.293
Hydroxychloroquine
Yes, n = 68	−2.29 ± 5.25	−1.88 ± 4.91	−0.44 ± 7.11
No, n = 56	−2.55 ± 6.05	−1.31 ± 5.36	−0.85 ± 7.61
p	0.798	0.540	0.756
Immunosuppressants
Yes, n = 46	−2.79 ± 6.55	−2.59 ± 6.06	−1.20 ± 8.32
No, n = 79	−2.18 ± 4.99	−1.06 ± 4.40	−0.29 ± 6.69
p	0.568	0.112	0.503
Oral glucocorticoids
Yes, n = 93	−2.73 ± 5.90	−2.13 ± 5.31	−1.47 ± 7.55
No, n = 32	−1.50 ± 4.61	−0.21 ± 4.24	1.83 ± 6.03
p	0.289	0.067	0.027^*
Daily oral glucocorticoids ≥ 7.5 mg for ≥ 3 mos
Yes, n = 52	−3.34 ± 5.51	−3.35 ± 4.75	−2.82 ± 7.09
No, n = 41	−1.93 ± 6.35	−0.54 ± 5.62	0.25 ± 7.86
p	0.265	0.012^*	0.051
Antiosteoporosis therapies
Yes, n = 22	0.33 ± 5.67	1.93 ± 5.34	4.41 ± 7.51
No, n = 103	−2.97 ± 5.43	−2.37 ± 4.75	−1.70 ± 6.84
p	0.013^*	< 0.0005^*	< 0.0005^*

Results are mean ± SD.
↵* Statistically significant difference.
↵** p value was Bonferroni-adjusted.